Respiratory stimulant drugs in the post-operative setting.

Abstract

Drug-induced respiratory depression (DIRD) is a common problem encountered post-operatively and can persist for days after surgery. It is not always possible to predict the timing or severity of DIRD due to the number of contributing factors. A safe and effective respiratory stimulant could improve patient care by avoiding the use of reversal agents (e.g., naloxone, which reverses analgesia as well as respiratory depression) thereby permitting better pain management by enabling the use of higher doses of analgesics, facilitate weaning from prolonged ventilation, and ameliorate sleep-disordered breathing peri-operatively. The purpose of this review is to discuss the current pharmaceutical armamentarium of drugs (doxapram and almitrine) that are licensed for use in humans as respiratory stimulants and that could be used to reverse drug-induced respiratory depression in the post-operative period. We also discuss new chemical entities (AMPAkines and GAL-021) that have been recently evaluated in Phase 1 clinical trials and where the initial regulatory registration would be as a respiratory stimulant.

• Authors: Francis J Golder, Matthew M Hewitt, James F McLeod
• Journal: Respiratory physiology & neurobiology (Respir Physiol Neurobiol) Vol. 189 Issue 2 Pg. 395-402 (Nov 01 2013) ISSN: 1878-1519 [Electronic] Netherlands
• PMID: 23791825 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2013 The Authors. Published by Elsevier B.V. All rights reserved.

Chemical References

• Respiratory System Agents

Topics

• Humans
• Postoperative Complications (diagnosis, drug therapy, physiopathology)
• Pulmonary Ventilation (drug effects, physiology)
• Respiratory Insufficiency (diagnosis, drug therapy, physiopathology)
• Respiratory System Agents (pharmacology, therapeutic use)